QIAGEN and GENCURIX, a leading molecular diagnostics company, announced a strategic collaboration to co-develop advanced oncology assays for the QIAcuityDx platform-a next-generation digital PCR system engineered for high-performance clinical diagnostics.
This partnership marks a major milestone as GENCURIX becomes the first development partner under QIAGEN’s newly launched QIAcuityDx Partnering Program. The collaboration lays the foundation for expanding the availability of in vitro diagnostic (IVD) assays on the QIAcuityDx Four platform, significantly broadening access to digital PCR-powered cancer diagnostics.
By combining QIAGEN’s cutting-edge QIAcuityDx technology with GENCURIX’s expertise in multiplex assay development, the partnership aims to deliver sensitive, cost-effective, and clinically actionable oncology assays. These assays will be developed for both tissue and liquid biopsy applications, offering laboratories and healthcare providers flexible global commercialization options through QIAGEN’s established distribution and partnership network.
Also Read: Waters Enhances Alliance iS HPLC System Software
“The QIAcuityDx Partnering Program is designed to enable the generation of a broad menu of IVD assays on the platform,” said Jonathan Arnold, Vice President and Head, Partnering for Precision Diagnostics at QIAGEN. “The first partnership in this program with GENCURIX is an exciting moment, giving our oncology testing customers access to high-quality IVD assays that complement other established methods such as qPCR and NGS. We look forward to working with GENCURIX within this promising partner program.”
“This strategic partnership with QIAGEN represents a major inflection point for expanding our oncology molecular diagnostic technologies into the global market,” said Sang Rae Cho, CEO at GENCURIX. “We are confident that the synergy between our diagnostic content and QIAGEN’s platform will lead to global-standard precision cancer diagnostic solutions.”